Last 12 months
Inside the activity.
0 purchase rows · 240 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 200 |
| Dec 2025 | 0 | 3 |
| Jan 2026 | 0 | 31 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 2 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 3 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 21, 2026 Filed Sep 22, 2026 20:15 UTC |
Sulzberger GabrielleDirector
|
GrantCommon Stock | 4.2565 | $1,164.89 | $4,958.35 |
DisclosureSEC source: 0001262388-26-000018 · wk-form4_1790108122.xml · nonDerivative · entry 1 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,012.4473 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document |
| September 21, 2026 Filed Sep 22, 2026 20:14 UTC |
LUCIANO JUAN RDirector
|
GrantCommon Stock | 13.6637 | $1,164.89 | $15,916.71 |
DisclosureSEC source: 0000059478-26-000091 · wk-form4_1790108065.xml · nonDerivative · entry 1 LUCIANO JUAN R · CIK 0001455792 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,956.8138 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document |
| September 21, 2026 Filed Sep 22, 2026 20:12 UTC |
Fyrwald J ErikDirector
|
GrantCommon Stock | 8.513 | $1,164.89 | $9,916.71 |
DisclosureSEC source: 0000059478-26-000089 · wk-form4_1790107969.xml · nonDerivative · entry 1 Fyrwald J Erik · CIK 0001343564 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,536.1308 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document |
| September 21, 2026 Filed Sep 22, 2026 20:11 UTC |
Alvarez RalphDirector
|
GrantCommon Stock | 10.6591 | $1,164.89 | $12,416.68 |
DisclosureSEC source: 0001310215-26-000017 · wk-form4_1790107902.xml · nonDerivative · entry 1 Alvarez Ralph · CIK 0001310215 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,838.2192 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document |
| September 09, 2026 Filed Sep 11, 2026 20:16 UTC |
Seymour MelissaEVP, Global Quality
|
GiftCommon Stock | 12 | $0.00 | $0.00 |
DisclosureSEC source: 0002032089-26-000004 · wk-form4_1789157763.xml · nonDerivative · entry 2 Seymour Melissa · CIK 0002032089 · EVP, Global Quality 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,038.373 Read SEC document |
| September 02, 2026 Filed Sep 4, 2026 20:18 UTC |
Hernandez EdgardoEVP & Pres., Mfg. Operations
|
GiftCommon Stock | 13 | $0.00 | $0.00 |
DisclosureSEC source: 0001861052-26-000006 · wk-form4_1788553126.xml · nonDerivative · entry 1 Hernandez Edgardo · CIK 0001861052 · EVP & Pres., Mfg. Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,082.717 Read SEC document |
| September 02, 2026 Filed Sep 4, 2026 20:17 UTC |
Dozier EricEVP, Chief People Officer
|
GiftCommon Stock | 216 | $0.00 | $0.00 |
DisclosureSEC source: 0001955972-26-000008 · wk-form4_1788553030.xml · nonDerivative · entry 1 Dozier Eric · CIK 0001955972 · EVP, Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,239.212 Read SEC document |
| August 17, 2026 Filed Aug 18, 2026 20:22 UTC |
Fyrwald J ErikDirector
|
GrantCommon Stock | 8.3815 | $1,183.16 | $9,916.66 |
DisclosureSEC source: 0000059478-26-000085 · wk-form4_1787084560.xml · nonDerivative · entry 1 Fyrwald J Erik · CIK 0001343564 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,418.1248 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document |
| August 17, 2026 Filed Aug 18, 2026 20:23 UTC |
LUCIANO JUAN RDirector
|
GrantCommon Stock | 13.4527 | $1,183.16 | $15,916.70 |
DisclosureSEC source: 0000059478-26-000087 · wk-form4_1787084623.xml · nonDerivative · entry 1 LUCIANO JUAN R · CIK 0001455792 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,918.0448 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document |
| August 17, 2026 Filed Aug 18, 2026 20:24 UTC |
Sulzberger GabrielleDirector
|
GrantCommon Stock | 4.1908 | $1,183.16 | $4,958.39 |
DisclosureSEC source: 0001262388-26-000016 · wk-form4_1787084689.xml · nonDerivative · entry 1 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,003.9096 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document |
| August 17, 2026 Filed Aug 18, 2026 20:21 UTC |
Alvarez RalphDirector
|
GrantCommon Stock | 10.4945 | $1,183.16 | $12,416.67 |
DisclosureSEC source: 0001310215-26-000015 · wk-form4_1787084504.xml · nonDerivative · entry 1 Alvarez Ralph · CIK 0001310215 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,744.788 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document |
| August 17, 2026 Filed Aug 18, 2026 20:20 UTC |
Jonsson PatrikEVP & President, LLY Int'l
|
SaleCommon Stock | 6,500 | $1,175.10 | $7,638,150.00 |
DisclosureSEC source: 0001786054-26-000006 · wk-form4_1787084453.xml · nonDerivative · entry 1 Jonsson Patrik · CIK 0001786054 · EVP & President, LLY Int'l 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 54,146.62 F1 · shares: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 17, 2026 Read SEC document |
| August 10, 2026 Filed Aug 11, 2026 20:31 UTC |
Zakrowski Donald ASVP, Finance, & CAO
|
SaleCommon Stock | 2,000 | $1,185.01 | $2,370,020.00 |
DisclosureSEC source: 0000059478-26-000083 · wk-form4_1786480313.xml · nonDerivative · entry 1 Zakrowski Donald A · CIK 0001561539 · SVP, Finance, & CAO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,525.89 F1 · shares: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 11, 2026. Read SEC document |
| August 07, 2026 Filed Aug 10, 2026 20:19 UTC |
Hakim AnatEVP, GC & Secretary
|
SaleCommon Stock | 5,000 | $1,190.00 | $5,950,000.00 |
DisclosureSEC source: 0001685556-26-000006 · wk-form4_1786393159.xml · nonDerivative · entry 1 Hakim Anat · CIK 0001685556 · EVP, GC & Secretary 10b5-1 filing: Plan reported Ownership: Indirect · By spouse Disclosed balance after: 11,875 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on February 10, 2026. F2 · ownership.nature: The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of her pecuniary interest therein. Read SEC document |
| August 01, 2026 Filed Aug 3, 2026 20:42 UTC |
Seymour MelissaEVP, Global Quality
|
Exercise / conversionRestricted Stock Unit · Derivative | 981 | $0.00 | $0.00 |
DisclosureSEC source: 0002032089-26-000002 · wk-form4_1785789751.xml · derivative · entry 3 Seymour Melissa · CIK 0002032089 · EVP, Global Quality 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 952 Underlying: Common Stock · 981 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. F2 · derivative.exercise_date: The restricted stock units vest in three installments, 952 on August 1, 2025, 981 on August 1, 2026, and 952 on August 1, 2027. F2 · derivative.expiration_date: The restricted stock units vest in three installments, 952 on August 1, 2025, 981 on August 1, 2026, and 952 on August 1, 2027. Read SEC document |
| August 01, 2026 Filed Aug 3, 2026 20:42 UTC |
Seymour MelissaEVP, Global Quality
|
Tax withholdingCommon Stock | 438.707 | $1,148.84 | $504,004.15 |
DisclosureSEC source: 0002032089-26-000002 · wk-form4_1785789751.xml · nonDerivative · entry 2 Seymour Melissa · CIK 0002032089 · EVP, Global Quality 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,067.373 Read SEC document |
| August 01, 2026 Filed Aug 3, 2026 20:42 UTC |
Seymour MelissaEVP, Global Quality
|
Exercise / conversionCommon Stock | 981 | $0.00 | $0.00 |
DisclosureSEC source: 0002032089-26-000002 · wk-form4_1785789751.xml · nonDerivative · entry 1 Seymour Melissa · CIK 0002032089 · EVP, Global Quality 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,506.08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 20, 2026 Filed Jul 21, 2026 20:39 UTC |
Fyrwald J ErikDirector
|
GrantCommon Stock | 8.6465 | $1,146.90 | $9,916.67 |
DisclosureSEC source: 0000059478-26-000066 · wk-form4_1784666337.xml · nonDerivative · entry 1 Fyrwald J Erik · CIK 0001343564 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,409.7433 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document |
| July 20, 2026 Filed Jul 21, 2026 20:39 UTC |
LUCIANO JUAN RDirector
|
GrantCommon Stock | 13.878 | $1,146.90 | $15,916.68 |
DisclosureSEC source: 0000059478-26-000068 · wk-form4_1784666385.xml · nonDerivative · entry 1 LUCIANO JUAN R · CIK 0001455792 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,904.5921 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document |
| July 20, 2026 Filed Jul 21, 2026 20:40 UTC |
Sulzberger GabrielleDirector
|
GrantCommon Stock | 4.3232 | $1,146.90 | $4,958.28 |
DisclosureSEC source: 0001262388-26-000014 · wk-form4_1784666431.xml · nonDerivative · entry 1 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,999.7188 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document |
| July 20, 2026 Filed Jul 21, 2026 20:37 UTC |
Alvarez RalphDirector
|
GrantCommon Stock | 10.8263 | $1,146.90 | $12,416.68 |
DisclosureSEC source: 0001310215-26-000013 · wk-form4_1784666268.xml · nonDerivative · entry 1 Alvarez Ralph · CIK 0001310215 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,734.2935 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document |
| June 15, 2026 Filed Jun 16, 2026 20:14 UTC |
Fyrwald J ErikDirector
|
GrantCommon Stock | 8.7809 | $1,129.35 | $9,916.71 |
DisclosureSEC source: 0000059478-26-000057 · wk-form4_1781640856.xml · nonDerivative · entry 1 Fyrwald J Erik · CIK 0001343564 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,401.0968 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document |
| June 15, 2026 Filed Jun 16, 2026 20:24 UTC |
LUCIANO JUAN RDirector
|
GrantCommon Stock | 14.0937 | $1,129.35 | $15,916.72 |
DisclosureSEC source: 0000059478-26-000059 · wk-form4_1781641479.xml · nonDerivative · entry 1 LUCIANO JUAN R · CIK 0001455792 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,890.7141 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document |
| June 15, 2026 Filed Jun 16, 2026 20:25 UTC |
Sulzberger GabrielleDirector
|
GrantCommon Stock | 4.3904 | $1,129.35 | $4,958.30 |
DisclosureSEC source: 0001262388-26-000012 · wk-form4_1781641539.xml · nonDerivative · entry 1 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,995.3956 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document |
| June 15, 2026 Filed Jun 16, 2026 20:13 UTC |
Alvarez RalphDirector
|
GrantCommon Stock | 10.9945 | $1,129.35 | $12,416.64 |
DisclosureSEC source: 0001310215-26-000011 · wk-form4_1781640779.xml · nonDerivative · entry 1 Alvarez Ralph · CIK 0001310215 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,723.4672 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document |
| June 10, 2026 Filed Jun 11, 2026 20:23 UTC |
Yuffa IlyaEVP&Pres, LLY USA&Global Capab
|
SaleCommon Stock | 2,500 | $1,150.77 | $2,876,925.00 |
DisclosureSEC source: 0001826001-26-000006 · wk-form4_1781209410.xml · nonDerivative · entry 1 Yuffa Ilya · CIK 0001826001 · EVP&Pres, LLY USA&Global Capab 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,804.111 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2026. Read SEC document |
| May 18, 2026 Filed May 19, 2026 20:17 UTC |
Fyrwald J ErikDirector
|
GrantCommon Stock | 10.036 | $988.09 | $9,916.47 |
DisclosureSEC source: 0000059478-26-000053 · wk-form4_1779221866.xml · nonDerivative · entry 1 Fyrwald J Erik · CIK 0001343564 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,279.592 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document |
| May 18, 2026 Filed May 19, 2026 20:18 UTC |
LUCIANO JUAN RDirector
|
GrantCommon Stock | 16.109 | $988.09 | $15,917.14 |
DisclosureSEC source: 0000059478-26-000055 · wk-form4_1779221928.xml · nonDerivative · entry 1 LUCIANO JUAN R · CIK 0001455792 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,850.832 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document |
| May 18, 2026 Filed May 19, 2026 20:19 UTC |
Sulzberger GabrielleDirector
|
GrantCommon Stock | 5.018 | $988.09 | $4,958.24 |
DisclosureSEC source: 0001262388-26-000010 · wk-form4_1779221994.xml · nonDerivative · entry 1 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,986.617 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document |
| May 18, 2026 Filed May 19, 2026 20:16 UTC |
Alvarez RalphDirector
|
GrantCommon Stock | 12.566 | $988.09 | $12,416.34 |
DisclosureSEC source: 0001310215-26-000008 · wk-form4_1779221785.xml · nonDerivative · entry 1 Alvarez Ralph · CIK 0001310215 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,627.279 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document |
| May 06, 2026 Filed May 7, 2026 20:00 UTC |
LILLY ENDOWMENT INCFormer 10% Shareholder
|
SaleCommon Stock | 2,208 | $996.18 | $2,199,572.06 |
DisclosureSEC source: 0000316011-26-000015 · form4-05072026_040501.xml · nonDerivative · entry 2 LILLY ENDOWMENT INC · CIK 0000316011 · Former 10% Shareholder 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,881,150 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $996.00 to $996.46, inclusive. Read SEC document |
| May 06, 2026 Filed May 7, 2026 20:00 UTC |
LILLY ENDOWMENT INCFormer 10% Shareholder
|
SaleCommon Stock | 13,620 | $995.23 | $13,554,964.50 |
DisclosureSEC source: 0000316011-26-000015 · form4-05072026_040501.xml · nonDerivative · entry 1 LILLY ENDOWMENT INC · CIK 0000316011 · Former 10% Shareholder 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,883,358 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $995.00 to $995.9963, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) and (2) to this Form 4. Read SEC document |
| April 20, 2026 Filed Apr 21, 2026 20:14 UTC |
Alvarez RalphDirector
|
GrantCommon Stock | 13.498 | $919.90 | $12,416.81 |
DisclosureSEC source: 0000059478-26-000034 · wk-form4_1776802466.xml · nonDerivative · entry 1 Alvarez Ralph · CIK 0001310215 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,614.713 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document |
| April 20, 2026 Filed Apr 21, 2026 20:16 UTC |
Fyrwald J ErikDirector
|
GrantCommon Stock | 10.78 | $919.90 | $9,916.52 |
DisclosureSEC source: 0000059478-26-000036 · wk-form4_1776802597.xml · nonDerivative · entry 1 Fyrwald J Erik · CIK 0001343564 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,269.556 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document |
| April 20, 2026 Filed Apr 21, 2026 20:18 UTC |
LUCIANO JUAN RDirector
|
GrantCommon Stock | 17.303 | $919.90 | $15,917.03 |
DisclosureSEC source: 0000059478-26-000038 · wk-form4_1776802736.xml · nonDerivative · entry 1 LUCIANO JUAN R · CIK 0001455792 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,834.723 Read SEC document |
| April 20, 2026 Filed Apr 21, 2026 20:20 UTC |
Sulzberger GabrielleDirector
|
GrantCommon Stock | 5.39 | $919.90 | $4,958.26 |
DisclosureSEC source: 0001262388-26-000008 · wk-form4_1776802850.xml · nonDerivative · entry 1 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,981.599 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document |
| March 16, 2026 Filed Mar 17, 2026 20:30 UTC |
Fyrwald J ErikDirector
|
GrantCommon Stock | 10.026 | $989.12 | $9,916.92 |
DisclosureSEC source: 0000059478-26-000023 · wk-form4_1773779424.xml · nonDerivative · entry 1 Fyrwald J Erik · CIK 0001343564 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,258.776 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document |
| March 16, 2026 Filed Mar 17, 2026 20:31 UTC |
LUCIANO JUAN RDirector
|
GrantCommon Stock | 16.092 | $989.12 | $15,916.92 |
DisclosureSEC source: 0000059478-26-000025 · wk-form4_1773779494.xml · nonDerivative · entry 1 LUCIANO JUAN R · CIK 0001455792 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,817.42 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document |
| March 16, 2026 Filed Mar 17, 2026 20:32 UTC |
Sulzberger GabrielleDirector
|
GrantCommon Stock | 5.013 | $989.12 | $4,958.46 |
DisclosureSEC source: 0001262388-26-000006 · wk-form4_1773779547.xml · nonDerivative · entry 1 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,976.209 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document |
| March 16, 2026 Filed Mar 17, 2026 20:29 UTC |
Alvarez RalphDirector
|
GrantCommon Stock | 12.553 | $989.12 | $12,416.42 |
DisclosureSEC source: 0001310215-26-000006 · wk-form4_1773779362.xml · nonDerivative · entry 1 Alvarez Ralph · CIK 0001310215 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,601.215 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document |
| February 19, 2026 Filed Feb 19, 2026 21:18 UTC |
Dozier EricEVP, Chief People Officer
|
GiftCommon Stock | 481 | $0.00 | $0.00 |
DisclosureSEC source: 0001955972-26-000006 · wk-form4_1771535926.xml · nonDerivative · entry 1 Dozier Eric · CIK 0001955972 · EVP, Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,455.212 Read SEC document |
| February 17, 2026 Filed Feb 18, 2026 21:25 UTC |
Fyrwald J ErikDirector
|
GrantCommon Stock | 9.572 | $1,036.05 | $9,917.07 |
DisclosureSEC source: 0000059478-26-000015 · wk-form4_1771449908.xml · nonDerivative · entry 1 Fyrwald J Erik · CIK 0001343564 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,120.322 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document |
| February 17, 2026 Filed Feb 18, 2026 21:26 UTC |
LUCIANO JUAN RDirector
|
GrantCommon Stock | 15.363 | $1,036.05 | $15,916.84 |
DisclosureSEC source: 0000059478-26-000017 · wk-form4_1771449964.xml · nonDerivative · entry 1 LUCIANO JUAN R · CIK 0001455792 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,772.019 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document |
| February 17, 2026 Filed Feb 18, 2026 21:27 UTC |
Sulzberger GabrielleDirector
|
GrantCommon Stock | 4.786 | $1,036.05 | $4,958.54 |
DisclosureSEC source: 0001262388-26-000004 · wk-form4_1771450040.xml · nonDerivative · entry 1 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,966.222 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document |
| February 17, 2026 Filed Feb 18, 2026 21:23 UTC |
Alvarez RalphDirector
|
GrantCommon Stock | 11.985 | $1,036.05 | $12,417.06 |
DisclosureSEC source: 0001310215-26-000004 · wk-form4_1771449826.xml · nonDerivative · entry 1 Alvarez Ralph · CIK 0001310215 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,491.627 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document |
| February 16, 2026 Filed Feb 18, 2026 21:22 UTC |
Zakrowski Donald ASVP, Finance, & CAO
|
Exercise / conversionRestricted Stock Unit · Derivative | 184 | $0.00 | $0.00 |
DisclosureSEC source: 0001561539-26-000004 · wk-form4_1771449773.xml · derivative · entry 4 Zakrowski Donald A · CIK 0001561539 · SVP, Finance, & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 184 shares Expires 2026-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 16, 2026 Filed Feb 18, 2026 21:22 UTC |
Zakrowski Donald ASVP, Finance, & CAO
|
Tax withholdingCommon Stock | 81.553 | $1,040.00 | $84,815.12 |
DisclosureSEC source: 0001561539-26-000004 · wk-form4_1771449773.xml · nonDerivative · entry 2 Zakrowski Donald A · CIK 0001561539 · SVP, Finance, & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,525.89 F1 · shares: The reported amount includes 7.458 shares previously withheld to satisfy tax withholding obligations arising prior to the vesting date of this award. Read SEC document |
| February 16, 2026 Filed Feb 18, 2026 21:22 UTC |
Zakrowski Donald ASVP, Finance, & CAO
|
Exercise / conversionCommon Stock | 184 | $0.00 | $0.00 |
DisclosureSEC source: 0001561539-26-000004 · wk-form4_1771449773.xml · nonDerivative · entry 1 Zakrowski Donald A · CIK 0001561539 · SVP, Finance, & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,607.443 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2026 Filed Feb 18, 2026 21:21 UTC |
Montarce LucasEVP & CFO
|
Exercise / conversionRestricted Stock Unit · Derivative | 368 | $0.00 | $0.00 |
DisclosureSEC source: 0001752447-26-000004 · wk-form4_1771449713.xml · derivative · entry 3 Montarce Lucas · CIK 0001752447 · EVP & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 368 shares Expires 2026-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 16, 2026 Filed Feb 18, 2026 21:21 UTC |
Montarce LucasEVP & CFO
|
Tax withholdingCommon Stock | 159.733 | $1,040.00 | $166,122.32 |
DisclosureSEC source: 0001752447-26-000004 · wk-form4_1771449713.xml · nonDerivative · entry 2 Montarce Lucas · CIK 0001752447 · EVP & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,258.473 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.